Hu E, Horning S J
J Biol Response Mod. 1987 Apr;6(2):121-9.
Twenty-two patients with advanced cancer were entered into a phase I study of recombinant human interferon beta (IFN-beta). The maximum tolerated dose was 100 X 10(6) IU administered intravenously on a three times weekly schedule, and persistent fever was the dose-limiting toxicity. The majority of patients tolerated administration of IFN-beta well with negligible hematologic toxicity. Details of the clinical effects of escalating doses of recombinant human IFN-beta, administered three times weekly, are described.
22例晚期癌症患者进入重组人干扰素β（IFN-β）的I期研究。最大耐受剂量为每周三次静脉注射100×10⁶国际单位，持续性发热是剂量限制性毒性。大多数患者对IFN-β的给药耐受性良好，血液学毒性可忽略不计。描述了每周三次给予递增剂量重组人IFN-β的临床效果细节。
